Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186686 | 0.85 | CYP4F2 (0.41) | CYP4F2CYP4A11HDAC4HDAC1 | |
| SCHEMBL5705263 | 0.84 | CYP4F2 (0.47) | CYP4F2CYP4A11 | |
| SCHEMBL187214 | 0.84 | CYP4F2 (0.51) | CYP4F2CYP4A11EPHX2HDAC1 | |
| SCHEMBL187126 | 0.83 | CYP4F2 (0.53) | CYP4F2CYP4A11EPHX2KMT2AHDAC1 | |
| SCHEMBL798199 | 0.75 | CYP4F2 (0.60) | CYP4F2CYP4A11EPHX2HDAC1 | |
| SCHEMBL797984 | 0.75 | CYP4F2 (0.60) | CYP4F2CYP4A11EPHX2HDAC1 | |
| SCHEMBL798227 | 0.75 | CYP4F2 (0.60) | CYP4F2CYP4A11EPHX2HDAC1 | |
| SCHEMBL798441 | 0.75 | CYP4F2 (0.60) | CYP4F2CYP4A11EPHX2HDAC1 | |
| SCHEMBL46318 | 0.72 | CYP4F2 (0.48) | CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL14892163 | 0.72 | CYP4F2 (0.65) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402300-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-04 | — | — | EP | disclosed |